Leerink Partnrs Issues Optimistic Outlook for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Research analysts at Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a research report issued on Wednesday, July 9th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.86) for the quarter, up from their previous forecast of ($0.87). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals' Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($3.47) EPS and FY2026 earnings at ($2.85) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.12). The firm had revenue of $37.72 million during the quarter, compared to the consensus estimate of $40.43 million. Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The company's quarterly revenue was up 25.9% on a year-over-year basis. During the same period in the prior year, the company posted ($2.35) EPS.

A number of other research firms have also recently issued reports on RYTM. Oppenheimer raised their price target on shares of Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the stock an "outperform" rating in a report on Thursday. Bank of America raised their target price on shares of Rhythm Pharmaceuticals from $73.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday. Stifel Nicolaus raised their target price on shares of Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Morgan Stanley set a $95.00 target price on shares of Rhythm Pharmaceuticals and gave the stock an "overweight" rating in a report on Wednesday. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 target price (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Rhythm Pharmaceuticals presently has an average rating of "Buy" and an average target price of $91.00.

Rhythm Pharmaceuticals Price Performance

Rhythm Pharmaceuticals stock opened at $86.70 on Monday. Rhythm Pharmaceuticals has a 1-year low of $40.61 and a 1-year high of $94.80. The firm has a market capitalization of $5.52 billion, a P/E ratio of -30.85 and a beta of 2.26. The company's 50-day moving average is $64.34 and its 200 day moving average is $59.31.

Insider Buying and Selling

In other news, CFO Hunter C. Smith sold 42,120 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $80.48, for a total value of $3,389,817.60. Following the transaction, the chief financial officer owned 116,915 shares of the company's stock, valued at approximately $9,409,319.20. This trade represents a 26.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Yann Mazabraud sold 6,745 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $65.08, for a total transaction of $438,964.60. Following the transaction, the executive vice president directly owned 37,655 shares in the company, valued at $2,450,587.40. The trade was a 15.19% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,673 shares of company stock worth $7,118,510. Insiders own 6.10% of the company's stock.

Institutional Trading of Rhythm Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its holdings in shares of Rhythm Pharmaceuticals by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 440,250 shares of the company's stock worth $24,645,000 after buying an additional 6,384 shares during the period. Raymond James Financial Inc. acquired a new stake in Rhythm Pharmaceuticals in the 4th quarter worth about $218,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Rhythm Pharmaceuticals in the 4th quarter worth about $341,000. Swiss National Bank raised its stake in Rhythm Pharmaceuticals by 1.0% in the 4th quarter. Swiss National Bank now owns 90,200 shares of the company's stock worth $5,049,000 after purchasing an additional 900 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new stake in Rhythm Pharmaceuticals in the 4th quarter worth about $287,000.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.